It is estimated that over 39 million people worldwide are infected with the human immunodeficiency virus (HIV). The introduction of protease inhibitors as part of the anti-HIV therapy has contributed to a huge reduction in the number of people who die from the acquired immunodeficiency syndrome (AIDS). However, the use of these drugs has been associated with new-onset diabetes; recent studies have confirmed a higher rate of diabetes among people with HIV, compared with the general population. This implies that a significant number of people, as well as suffering the effects of the virus, may eventually be at risk of disabling or life threatening diabetes complications, such as kidney failure or heart disease. In this article, Cecilia Yoon describes the links between HIV and its treatment and diabetes.
HIV, AIDS, protease inhibitors, HAART, retrovirus, triglycerides, lipodystrophy syndrome,